Form 4: SOPHiA GENETICS CEO Receives Equity Awards
Insider Transaction
SOPHiA GENETICS SA reports that CEO Jurgi Camblong was granted restricted stock units and stock options.
Summary
- Jurgi Camblong, CEO of SOPHiA GENETICS SA, received a grant of 431,211 ordinary shares as restricted stock units (RSUs) on April 2, 2026.
- Additionally, Camblong was granted stock options to purchase 628,743 ordinary shares at an exercise price of $5.04 per share.
- The RSUs are subject to vesting based on continued service, with 25% vesting on April 2, 2027, and the remainder vesting quarterly through April 2, 2030.
- The stock options also vest over time, with 25% vesting on April 2, 2027, and the remaining vesting monthly through April 2, 2030.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents standard executive compensation practices and a commitment from the CEO, but does not contain new financial performance data.
Positives
- CEO Jurgi Camblong received a significant grant of RSUs (431,211 shares) and stock options (628,743 shares), indicating management's long-term commitment and potential for future value creation.
- The equity awards are structured with multi-year vesting schedules (through April 2, 2030), aligning management's incentives with the company's long-term performance and shareholder value.
Risks
- The value of the RSUs and stock options is contingent on the continued service of the reporting person, meaning any departure before vesting would result in forfeiture.
- The stock options have an exercise price of $5.04, meaning they will only be profitable if the company's share price rises above this level.
Future Outlook
The vesting schedules for the RSUs and stock options extend through April 2, 2030, indicating a long-term outlook for the company's performance and the reporting person's continued involvement.
Industry Context
StockSavvy.ai notes that the issuance of equity awards to key executives, such as RSUs and stock options, is a common practice in the biotechnology and healthcare technology sectors to attract, retain, and incentivize talent, aligning their interests with long-term company growth and shareholder value.
Stakeholder Impact
- Shareholders: The grants align management's interests with long-term shareholder value creation, but the immediate impact on share price is minimal as these are standard compensation awards.
Next Steps
- Vesting of RSUs and stock options according to the specified schedules through April 2, 2030.
Key Dates
| Date | Description |
|---|---|
| 04/02/2026 | Earliest transaction date; date of RSU grant and stock option grant. |
| 04/02/2027 | First vesting date for 25% of RSUs and 25% of stock options. |
| 04/02/2030 | Final vesting date for remaining RSUs and stock options. |
| 04/03/2026 | Date of filing signature. |
Keywords
SOPHiA GENETICS SA, Jurgi Camblong, Form 4, SEC Filing, Equity Awards, Restricted Stock Units, Stock Options, CEO, Insider Trading, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.